OncoMatch/Clinical Trials/NCT03826992
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Is NCT03826992 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Vyxeos and Venetoclax for leukemia.
Treatment: Vyxeos · Venetoclax — This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: KMT2A (MLL) rearranged
KMT2A-rearranged ALL
Excluded: KMT2A (MLL) rearrangement
MPAL with KMT2A-rearrangement are NOT eligible
Excluded: BCR t(9;22)
Philadelphia chromosome t(9;22) positive leukemia (Ph+ ALL, AML, MPAL, or AUL)
Prior therapy
Must have received: hematopoietic stem cell transplant
Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant (HSCT)
Must have received: anthracycline
Fully recovered from acute toxicities of ... Anthracycline Exposure
Cannot have received: growth factors
Receipt of growth factors within 7 days prior to enrollment
Cannot have received: radiation therapy
Exception: greater than 13.6 Gray (Gy) prior radiation to the mediastinum
Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum
Lab requirements
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify